6th Global Symposium on Ketogenic Therapies for Neurological Disorders

摘要 生酮饮食(KD)是一种公认的治疗难治性癫痫的方法，自1921年在 明尼苏达州罗切斯特市的梅奥诊所。虽然科学家们仍在继续研究其广泛的抗惊厥作用 越来越多的实验证据表明，它具有改善疾病和保护神经的作用。在这 快速发展的领域出现了关于机制的新数据和支持更广泛使用的证据 KD(及其变种)可对抗多种神经系统疾病，包括癌症、偏头痛、自闭症和痴呆症。 尽管有效和负担得起，但世界上大部分地区都不提供KD疗法--特别是在 东南亚、东欧和非洲。有兴趣提供KD的中心可以选择不这样做 由于感知到的资源不足，熟悉KD的医生和/或营养师可能缺席。 此外，关于机制、应用和协议的最新研究可能没有得到很好的传播， 而缺乏标准化的协议和管理建议也带来了额外的障碍。 如果没有足够的支持，患者可能不会考虑这种治疗方法，因为它具有限制性。国际 科学家、医生、营养师、护士、社会工作者和学生都需要开会 并讨论了KD领域的方案、研究创新、临床经验和合作。 第六届全球生酮疗法研讨会是一个成功和不断发展的两年期系列会议的一部分。 第一届，癫痫和其他神经疾病的饮食疗法国际研讨会 (亚利桑那州凤凰城，2008)，得到了NIH的支持，并成为该系列中的第一个，建立了高水平的 为随后的成功研讨会提供科学和参与(爱丁堡，2010年；芝加哥，2012年；利物浦， 2014年；班夫，2016年)。它还建立了持久的合作精神和共同目标。六号 全球生酮疗法研讨会(2018年，韩国济州岛)代表着又一次飞跃： 重点仍然是促进临床和基础科学家之间的协作互动 受训人员，并向社区和其他地方传播最新研究成果，并强烈强调 将重点放在标准化和加强国际传播和实施上。至 实现最高的国际影响力来自世界各地的专家将分享他们的数据和经验， 将为来自资源有限地区的与会者举办教育课程，数量有限 培训了KD专家。我们延续了让年轻的专业人士、女性和其他人 并像以往的研讨会一样，为所有与会者提供合作精神和动力 以进一步利用代谢疗法。为与会者的参与度和团队安排了充足的时间 讨论，这是以往专题讨论会的一个广受欢迎和强有力的特点。教职员工和主持人是 国际公认的专家和第六届全球研讨会是继续 神经疾病新陈代谢疗法的进展和倡导。

SUMMARY The ketogenic diet (KD) is an established therapy for drug-resistant epilepsy since its origins in 1921 at the Mayo Clinic in Rochester, Minnesota. While scientists continue to study its broad anticonvulsant effects there is mounting experimental evidence for disease-modifying and neuroprotective properties. In this rapidly advancing field there is emerging data on mechanisms and evidence supporting broader use of the KD (and variants) against diverse neurological conditions including cancer, migraine, autism and dementia. Despite efficacy and affordability large regions of the world do not offer KD therapy – particularly in Southeast Asia, Eastern Europe and Africa. Centers interested in offering KD may elect not to do so because of perceived inadequate resources; physicians and/or dietitians familiar with KD may be absent. Furthermore, the latest research on mechanisms, applications and protocols may not be well disseminated, and a lack of standardized protocols and management recommendations present additional barriers. Without adequate support patients may not consider this treatment due to its restrictiveness. International meetings are needed where scientists, physicians, dietitians, nurses, social workers and students can meet and discuss protocols, research innovation, clinical experience and collaboration in the KD field. The Sixth Global Symposium on Ketogenic Therapies is part of a successful and evolving biennial series. The first, the International Symposium on Dietary Therapies for Epilepsy and Other Neurological Disorders (Phoenix, Arizona, 2008), was NIH-supported and became the first in the series, establishing a high level of science and participation for subsequent successful symposia (Edinburgh, 2010; Chicago, 2012; Liverpool, 2014; Banff, 2016). It also established an enduring collaborative spirit and common purpose. The Sixth Global Symposium on Ketogenic Therapies (Jeju Island, Korea, 2018) represents another leap forward: the focus remains on promoting collaborative interactions among clinical and basic scientists and trainees, and disseminating the latest research to the community and beyond, and a strong emphasis is placed on standardizing and enhancing international dissemination and implementation. To achieve the highest international impact experts from around the world will share their data and experience, and education sessions will be held for attendees from resource-limited regions with a limited number of trained KD experts. We continue the tradition of bringing young professionals, women and people with disabilities into the field, and, like previous symposia, offer all attendees a collaborative spirit and motivation to further leverage metabolic therapies. Ample time is scheduled for attendee engagement and group discussions, a well-received and robust feature of previous symposia. The faculty and moderators are internationally recognized experts and the Sixth Global Symposium is the definitive venue for continued progress in and advocacy for metabolism-based therapies for neurological disorders.